Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 11;40(1):165.
doi: 10.1186/s13046-021-01963-1.

The potential role of the extracellular matrix in the activity of trabectedin in UPS and L-sarcoma: evidences from a patient-derived primary culture case series in tridimensional and zebrafish models

Affiliations

The potential role of the extracellular matrix in the activity of trabectedin in UPS and L-sarcoma: evidences from a patient-derived primary culture case series in tridimensional and zebrafish models

Alessandro De Vita et al. J Exp Clin Cancer Res. .

Abstract

Background: Soft tissue sarcomas (STS) are a rare group of solid neoplasm including among others liposarcoma, leiomyosarcoma (L-sarcoma) and undifferentiated pleomorphic sarcoma (UPS) entities. The current first-line treatment is represented by anthracycline based- regimens, second-line may include trabectedin. Currently the activity of trabectedin and its mechanism of action is not completely elucidated.

Methods: Taking the advantages of our 3D patient-derived primary culture translational model we performed genomic-, chemobiogram, proteomic- and in vivo analysis in a UPS culture (S1). Furthermore pharmacological profiling of a UPS and L-sarcoma patient-derived case series and in silico analysis were carried out.

Results: Trabectedin exhibited an increased activity in 3D respect to 2D cultures suggesting an extracellular matrix (ECM) and timp1 involvement in its mechanism of action. Moreover 3D S1 xenotranspanted zebrafish model showed an increased sensitivity to trabectedin. Finally the results were further validated in a UPS and L-sarcoma case series.

Conclusions: Taken together these results confirmed the activity of trabectedin in these STS histotypes. Moreover the data underline the ECM involvement in the cytotoxic effect mediated by trabectedin and could open the door for researches aimed to focus on the patient setting that could benefit from this agent.

Keywords: 3D scaffold; Chemotherapy; Extracellular matrix; Patient‐derived primary cultures; Trabectedin; Undifferentiated pleomorphic sarcoma and L-sarcoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no competing interests.

Figures

Fig. 1
Fig. 1
a hematoxylin and eosin staining of the patient surgical specimen showing high-grade polymorphic UPS cells (light blue stroma) infiltrating necrotic tissue, 10 x and 20 x magnification. b hematoxylin and eosin staining of the cytospunned tumor cells from the patient-derived UPS primary culture S1, 10 x and 20 x magnification. c hematoxylin and eosin staining of the cytospunned tumor cells (light blue spots) from the patient-derived UPS primary culture S1 cultured within 3D collagen-based scaffold system, 10 x and 20 x magnification. d Heat map comparisons of the relative gene expression of selected tumor-associated markers tgf-b, slug, snail, mmp9 between UPS patient surgical specimen, S1 patient-derived 2D standard monolayer primary culture and S1 patient-derived 3D primary culture system. e hematoxylin and eosin staining of the patient surgical specimen showing low and high grade UPS and L-sarcoma (light blue stroma) infiltrating adipose tissue, 10x and 20× magnification. f hematoxylin and eosin staining of the cytospunned tumor cells of patient-derived primary cultures UPS and L-sarcoma case series, 10 x and 20 x magnification
Fig. 2
Fig. 2
a Chemobiogram analysis of S1 primary culture seeded in 2D and 3D-collagen based scaffold and exposed to chemotherapeutics agent, untreated cells were used as control. b Representative images of 2D and 3D-collagen based scaffold S1 primary culture exposed to the tested drugs. c DNA fragmentation analysis expressed as apoptotic cells % of 2D and 3D-collagen based scaffold S1 primary culture exposed to the tested drugs. d Representative images (dot plot) of DNA fragmentation analysis obtained thought flow cytometry
Fig. 3
Fig. 3
a Proteomic analysis of apoptotic- and anti-apoptotic-related proteins in 2D S1 primary culture exposed to the tested drugs. b Densitometric analysis of protein bands % normalized on the housekeeping vinculin. c Proteomic analysis of apoptotic- and anti-apoptotic-related proteins in 3D-collagen based scaffold S1 primary culture exposed to the tested drugs. d Densitometric analysis of protein bands % normalized on the housekeeping vinculin
Fig. 4
Fig. 4
a-c Relative expression of ECM-associated genes in 2D and 3D-collagen based scaffold S1 primary culture. d timp1/mmp2 relative expression ratio genes in 2D and 3D-collagen based scaffold S1 primary culture. e timp1/mmp9 relative expression ratio genes in 2D and 3D-collagen based scaffold S1 primary culture
Fig. 5
Fig. 5
a Representative fluorescence microscopy images of zebrafish embryos xenotrasnplanted with S1 cultured in standard monolayer culture (2D) and within 3D collagen-based scaffold (3D). Images of embryos untreated at 2 and 72 h post injection and exposed to trabectedin at 72 h post injection, scale bar 1000 μm. b Mean fluorescence signal of 2D and 3D xenotransplanted embryos, arbitrary units. c Tumor growth inhibition rate between 2D and 3D groups
Fig. 6
Fig. 6
Pharmacological profile of 2D and 3D-collagen based scaffold UPS and L-sarcoma primary culture case series. Primary cells were exposed to selected first- and second- line treatments (EPI, TRABE, ERI, DACA) for STS. Images of the surgical specimens used for the establishment of primary cultures are reported (a) S2 DDLPS. b S3 DDLPS. c S4 ALT/WDLPS. d S5 LMS. e S6 ALT/WDLPS. f S7 ALT/WDLPS. g S8 UPS. h DDLPS. i PLS

References

    1. Siegel RL, Miller KD, Jemal A, Cancer statistics. 2019. CA Cancer J. Clin. 69, 7–34 (2019). 10.3322/caac.21565. - PubMed
    1. Fletcher CD. The evolving classification of soft tissue tumours – an update based on the new 2013 WHO classification. Histopathology. 2014;64:2–11. doi: 10.1111/his.12267. - DOI - PubMed
    1. Casali PG, Abecassis N, Bauer S, Bauer S, Biagini R, Bielack S, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv51–67. doi: 10.1093/annonc/mdy096. - DOI - PubMed
    1. Ducimetière F, Lurkin A, Ranchère-Vince D, Decouvelaere AV, Péoc’h M, Istier L,et al. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS One. 2011;6:e20294. 10.1371/journal.pone.0020294. - PMC - PubMed
    1. Judson I, Verweij J, Gelderblom H, Hartmann JT, Schöffski P, Blay JY, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014;15:415–23. doi: 10.1016/S1470-2045(14)70063-4. - DOI - PubMed

Substances

LinkOut - more resources